Suzhou Highfine Biotech's significant net income growth rate, attributed to high earnings retention and efficient management, is seen as a positive despite a weak ROE. Analysts forecast accelerated future earnings.

Discrepancy over Suzhou Highfine Biotech's reported profits and lack of free cashflow over past year raises queries about its earnings power. Despite EPS growth in three years, potential risks and warning signs are noteworthy.